Business Information
The group's principal activity is to develop, manufacture and market newborn screening products for the identification and monitoring of common medical disorders that may occur during the critical development period of infants. The group's main products include algo series, which use automated auditory brainstem response technology, or aabr, to enable simple, non-invasive and accurate screening for hearing impairment in newborns and the co-stat analyzers which accurately and non-invasively measure the rate of hemolytic through the detection of carbon monoxide in exhaled breath. The group's customers include hospitals, clinics, laboratories, physicians, nurses, audiologists and governmental agencies. On 01-Jul-2003, the group acquired neometrics inc and on 29-Sep-2004, acquired fischer-zoth gmbh.
|
|
Name |
Title
|
Email
|
| Robert Gunst | Chmn. | Available | | Steven Murphy | VP - Finance, CFO | Available | | Christopher Chung | VP - Medical Affairs, Research & Development, and Engineering | Available | | Kenneth Traverso | VP - Marketing, Sales | Available | | William Mince | VP - Operations | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 89,915 | (927) | | 2005 | 43,045 | 6,152 | | 2004 | 36,506 | (2,407)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
